Abstract 434P
Background
High Grade Glioma include all grade III/IV primary brain tumors of Astrocytic, oligodendroglial and mixed cellular lineage and are associated with poor prognosis. The standard of care for high grade glioma is concomitant chemoradiation and Temozolomide with median survival of 12-15 months in glioblastoma and 2-5 years with newly diagnosed anaplastic gliomas. Prognosis is poor with the median survival of 3-9 months at first recurrence which drops to few weeks for more than 90% of the patients at second or subsequent recurrence. Our main objective is to determine Progression free survival after first and second line of treatment and Overall survival in patients with high grade glioma at a tertiary care center in Pakistan.
Methods
Patients with newly diagnosed High Grade Glioma after surgical resection and biopsy are assigned to recieved standard of care treatment i.e concomitant chemoradiation and temozolomide and was followed and on recurrence received Bevacizumab 10mg/kg with or without Irinotecan 125mg/m2 every 3 weekly.
Results
From 2016 to 2021, total of 117 newly diagnosed patients with High grade Glioma presented at Oncology department of Aga Khan University Hospital were included. Majority were male 80 (68.38) and the median (IQR) age was 51 (41-60%). Among high grade glioma majority have GBM (66%). 64% underwent subtotal resection, 23% and 11% had Gross total resection and biopsy respectively. Most of the patients 87 (74.3%) recieved concomitant chemoradiation followed by Temozolomide until disease progression as a systemic treatment. Moreover 75 (64.10%) patients recieved Irinotecan and Bevacizumab as a second line treatment. The median (IQR) progression free survival after primary treatment was 18 (11-29) months and 14 (12-24) months after second line treatment. Two third of the patients were dead at the end of follow up 74 (63.25%). The median (IQR) overall survival was 37 (26-46) months.
Conclusions
Our data reveal that combination of Bevacizumab and Irinotecan improves the outcome in high grade glioma when compared to historical results. Survival rates were high as reported in international studies. Should be used as standard of care in recurrent high grade glioma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
442P - Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer
Presenter: Tejaswini Adadadara
Session: Poster viewing 06
444P - Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study
Presenter: Elodie HIRIGOYEN
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06